Cargando…
IMPACT OF THE PEGYLATED-INTERFERON AND RIBAVIRIN THERAPY ON THE TREATMENT-RELATED MORTALITY OF PATIENTS WITH CIRRHOSIS DUE TO HEPATITIS C VIRUS
Although the protease inhibitors have revolutionized the therapy of chronic hepatitis C (CHC), the concomitant use of pegylated-interferon (PEG-IFN) and ribavirin (RBV) is associated to a high rate of adverse effects. In this study, we evaluated the consequences of PEG-IFN and RBV and their relation...
Autores principales: | DRESCH, Kelly Fernanda Nomura, de MATTOS, Angelo Alves, TOVO, Cristiane Valle, de ONOFRIO, Fernanda Quadros, CASAGRANDE, Leandro, FELTRIN, Alberi Adolfo, de BARROS, Iago Christofoli, de ALMEIDA, Paulo Roberto Lerias |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Instituto de Medicina Tropical
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879994/ https://www.ncbi.nlm.nih.gov/pubmed/27253739 http://dx.doi.org/10.1590/S1678-9946201658037 |
Ejemplares similares
-
Nutritional evaluation in cirrhosis: Emphasis on the phase angle
por: Fernandes, Sabrina Alves, et al.
Publicado: (2016) -
Hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis
por: Tovo, Cristiane Valle, et al.
Publicado: (2023) -
Treatment of chronic hepatitis C in patients with chronic kidney disease with Sofosbuvir-basead regimes
por: Rossato, Giovana, et al.
Publicado: (2019) -
Incidence of hepatocellular carcinoma in outpatients with cirrhosis in Brazil: A 10-year retrospective cohort study
por: Appel-da-Silva, Marcelo Campos, et al.
Publicado: (2016) -
HEPATOCELLULAR CARCINOMA IN A NON-CIRRHOTIC PATIENT WITH SUSTAINED
VIROLOGICAL RESPONSE AFTER HEPATITIS C TREATMENT
por: de MATTOS, Angelo Alves, et al.
Publicado: (2015)